GPBAR1 and metabolic dysfunction-associated steatotic liver disease: First, although new strategies, such as probiotics, prebiotics, FMT, phage therapy and FXR/TGR5 agonists, have shown promise in the treatment of NAFLD, challenges in developing safe and effective therapeutic drugs, including the selectivity, tissue specificity and drug resistance for long-term use, remain further assessed.